# Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

> **NCT00791544** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 13 (actual)

## Conditions studied

- Liver Carcinoma

## Interventions

- **DRUG:** AVE1642
- **DRUG:** sorafenib
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00791544
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns
- **Last updated:** 2010-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791544, "Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00791544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*